PMS Registry
Company Name
Bayer Taiwan Co., Ltd.
Protocol Number
21124
Title of Study
RAPIT/ Safety and Effectiveness of Xofigo® (Radium-223 dichloride) in Routine Clinical Practice Settings in Taiwan)
Primary Objective
To describe the safety profiles and the effectiveness of Radium-223 in CRPC patients with symptomatic bone metastases under routine clinical practice in Taiwan.
The objective of the extended follow-up period (up to 2 years after the first injection of Radium-223) is to describe the long term safety information (i.e. hematological AEs, events of bone fracture or osteoporosis), and survival in CRPC patients post-treatment of Radium-223 under real-world practice in Taiwan.
Number of Sites
10
Period of Study
From:2020 Q3 to:2023 Q4
Number of Patients
300人
IRB Approval Date
NTUH 2020/03/17
TPVGH 2020/05/01
CGMHLK 2020/04/29
KFSYSCC In Process
TSGH 2020/04/18
CMUH 2020/05/07
TCVGH 2020/05/25
CYCH 2020/05/20
KMUH 2020/05/07
CHIMEI In Process
Publication Plan / Date
2024 Q1